Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

4.6%

3 terminated out of 65 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed with results

Key Signals

7 with results83% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (21)
Early P 1 (3)
P 1 (3)
P 2 (9)
P 3 (1)
P 4 (1)

Trial Status

Recruiting31
Completed15
Not Yet Recruiting11
Terminated3
Enrolling By Invitation2
Active Not Recruiting2

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (65)

Showing 20 of 20 trials
NCT07569419Early Phase 1RecruitingPrimary

Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

NCT07108153Phase 2Active Not RecruitingPrimary

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

NCT07568119Active Not RecruitingPrimary

Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care

NCT07223255Not ApplicableRecruitingPrimary

Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet

NCT06595420RecruitingPrimary

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

NCT07135869RecruitingPrimary

Muscle Fatigue in People With Cystic Fibrosis: Insight From a Mobile App

NCT06645782Not ApplicableCompletedPrimary

Group Cognitive Behavioural Therapy for Adults With Cystic Fibrosis

NCT07559175Phase 2Not Yet Recruiting

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07192679RecruitingPrimary

MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis

NCT07314229Not ApplicableRecruitingPrimary

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

NCT07508904Not ApplicableRecruitingPrimary

Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis

NCT06984679RecruitingPrimary

Physical Impairments in Children With Cystic Fibrosis

NCT07484607RecruitingPrimary

Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis

NCT06940531RecruitingPrimary

Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

NCT06616857Not ApplicableRecruitingPrimary

Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis

NCT07454681Not Yet RecruitingPrimary

MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .

NCT07450547Phase 2Not Yet Recruiting

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07436351Not ApplicableRecruitingPrimary

ACT With CF Self-Help Toolkit

NCT07442682Enrolling By Invitation

Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center

NCT07303621RecruitingPrimary

Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population

Scroll to load more

Research Network

Activity Timeline